Citations

Clear

15 citation(s) found for "Miller, Joshua R".

Risk outcome assessment with novel long-T ITC complex and high sensitivity troponin I and T in patients with suspected acute coronary syndromes: MERITnI substudy
Apple, F S, Wagner, Barret P., Sandoval, Yader, Brown, Hannah M. , Miller, Joshua, Sexter, Anne, Schulz, Karen, Jaffe, Allan S., Buda, Kevin G , Buda, Kevin , Wagner, Barrett , Sandoval, Yader , Smith, Stephen W. , Brown, Hannah M., Schulz, Karen , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | July 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1515/cclm-2026-0790 | PMID 42503204 Get It

Abstract Objectives Understanding whether the novel long-T ITC complex might assist in interpreting clinical prognostic utility compared to established cardiac biomarkers is needed. We determined long term major adverse cardiac events (MACE) and all-cause mortality (ACM) predicated on novel long-T ITC complex and high sensitivity cardiac troponin I (hs-cTnI) and T (hs-cTnT) assays in the emergency department (ED). Methods cTn assays were measured on the Mindray CL-1200i platform at presentation in consecutive patients enrolled in ‘Mindray hs-cTnI Assay Analytical and Clinical Evaluation for the Diagnosis and RIsk Assessment of Myocardial InfarctIon’ (MERITnI) (NCT05853042) trial with suspected ischemia. Sex specific 99th percentiles upper reference limits (URLs) were: hs-cTnI female 14 ng/L, male 15 ng/L; hs-cTnT female 10 ng/L, male 19 ng/L; long-T ITC complex 0.9 ng/L, same for female and male. Results Of 1,070 patients, 59.4 % were male, 43.4 % White, 45.5 % Black, and 39.5 % ≥65 years. Independent of biomarkers, a continuum of risk over 1 year showed MACE increased to 16.1 % and ACM to 16.5 %. Long-T ITC complex did not show a continuum change, increasing only 0.1 % (HR: 1.001 (1.0–1.001) per ng/L. However, hs-cTnI increased 1.8 % (HR: 1.018 [1.009–1.027] for each ng/L (p<0.0001) and hs-cTnT increased 0.3 % per ng/L (HR: 1.003 [1.001–1.006]) (p=0.0028). Between subjects ≤URLs and >URLs, MACE and ACM all biomarkers showed significant (p<0.0001) differences over 1 year. For MACE in those >URL long-T ITC complex increased 11.2–25.2 %, hs-cTnI 18.0–35.0 % and hs-cTnT 8.9–24.2 %. For ACM in those >URL long-T ITC complex increased 4.5–23.3 %, hs-cTnI 5.0–26.2 %, and hs-cTnT 3.6–24.1 %. Conclusions Novel long-T ITC complex did not provide new prognostic value to either hs-cTnI or hs-cTnT. Patients with increased hs-cTnI and hs-cTnT concentrations had marked increases in MACE and ACM risk at 1-year.
Distinguishing Acute Myocardial Infarction from Other Forms of Cardiac Injury with the Cardiac Troponin Long-T ITC Complex and High-Sensitivity Troponin I and T in Patients with Suspected Acute Coronary Syndrome: MERITnI Substudy
Apple, Fred S, Wagner, Barret P., Sandoval, Yader, Smith, Stephen W, Brown, Hannah M. , Miller, Joshua R, Sexter, Anne, Schulz, Karen, Jaffe, Allan S, Miller, Joshua R. , Buda, Kevin G , Sandoval, Yader , Brown, Hannah M , Miller, Joshua R , Apple, Fred S. , Buda, Kevin , Wagner, Barrett , Sandoval, Yader , Schulz, Karen , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry | July 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/clinchem/hvag098 | PMID 42621672 Get It

Abstract Background We determined whether circulating cardiac troponin I–cardiac troponin T–troponin C (ITC) complex containing long-form cardiac troponin T (long-T ITC) complex and ratios of high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) could differentiate myocardial infarction (MI) from chronic and acute non-MI myocardial injuries in patients with suspected acute coronary syndrome. Methods We measured long-T ITC complex, hs-cTnI, and hs-cTnT (Mindray) at 0- and 2-h in consecutive patients enrolled in the Mindray hs-cTnI Assay Analytical and Clinical Evaluation for the Diagnosis and RIsk Assessment of Myocardial InfarctIon (MERITnI) trial. Results Among the 882 subjects studied (median 3.0 h presentation), 47 had acute MI (5.3%), 116 had acute non-MI myocardial injury, and 90 had chronic myocardial injury. At 0 and 2 h, areas under the curve (AUC) significantly differentiated acute MI from chronic myocardial injury for long-T ITC complex (0.72 and 0.81, respectively; P = 0.0082) but not acute non-MI myocardial injury (AUC, 0.65 and 0.69, respectively; P = 0.23). 0 and 2 h AUCs for long-T ITC complex/hs-cTnT and hs-cTnI/hs-cTnT ratios also significantly differentiated acute MI from chronic myocardial injury (AUC, 0.79 and 0.86, respectively) and acute non-MI myocardial injury (AUC, 0.68 and 0.71, respectively). There was no biomarker concentration or ratio value discrimination between type 1 and type 2 MIs. Conclusions Long-T ITC concentrations and long-T ITC complex/hs-cTnT and hs-cTnI/hs-cTnT ratios may clinically assist in differentiating acute MI from non-MI myocardial injuries when evaluating patients with suspected acute coronary syndrome. ClinicalTrials.gov Registration Number: NCT05853042.
50 Use of Sodium-Glucose Cotransporter-2 Inhibitors Does Not Significantly Alter the Predicted 24-Hour Urine Protein Excretion Based Upon the Urinary Protein to Osmolality Ratio
Larson, Timothy S., Miller, Joshua R. , Lieske, John C.

Mayo Clinic

American Journal of Clinical Pathology | November 12, 2025 | Volume: 164 | Issue: Supplement_1 | Pages: No page available

10.1093/ajcp/aqaf121.477 Get It

Abstract Quantifying urine protein is critical for detecting and monitoring kidney disease. However, screens for proteinuria are unable to detect low levels of albuminuria. For this reason, our institution has long measured urinary total protein and osmolality on routine urinalysis specimens (RUS) and calculated a predicted 24-hour protein excretion (PER) based upon the protein to osmolality ratio (POR). Within the last decade, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been approved by the United States Food and Drug Administration (FDA) as a treatment for adults with type 2 diabetes mellitus, and these agents appear to be beneficial for many forms of proteinuric renal disease and confer renal protection. Therefore, we investigated whether the expected glucosuria and increase in urine osmolality while on SGLT2i would significantly alter the POR, and hence predicted PER, via a retrospective analysis of residual timed and randomly collected urine specimens. Between January 1st, 2014, until January 29th, 2025, 5820 patients with nearly contemporaneous (collected within one week of each other) timed collections and RUS were identified that included 5656 not on SGLT2i (Cohort A) and 164 patients prescribed SGLT2i (Cohort B). Total protein concentrations were assessed using a Roche Cobas c701 by using benzethonium chloride. The osmolality was determined via freezing point depression using a Precision Systems Inc Multi-OSMETTE, whereas glucose measurements were made using either an Arkray AX-4030 with AUTION Stick 9EB test strips or a Clinitek Status with Multistix 10 SG reagent strips. Predicted 24-hour protein results were then calculated from the POR using a published formula based upon prior clinical studies: 10(x·[log(protein/osmolality)]+y where x is 0.908 or 0.953 for males and females, respectively, and y is 2.8254 or 2.9739 for males and females, respectively. In Cohort A, there was good correlation between the predicted and measured 24-hour PER (Spearman correlation coefficient, ρ = 0.78), although the predicted PER underestimated the measured PER (Passing-Bablok regression, y = 1.54x-20.97 mg/24 hr). Importantly, a strong correlation (ρ = 0.93) and similar distribution (p=0.17) were found between the predicted and measured PER in Cohort B, with a much-reduced proportional bias (y = 1.06x+62.96 mg/24 hr). Furthermore, comparison of the difference between the predicted and measured PER between the two cohorts demonstrated the same prediction accuracy (p = 0.65), with a median difference (interquartile range) of 79 mg/24 hr (256) and 109 mg/24 hr (480) for Cohort A and B, respectively. Finally, a strong correlation (ρ = 0.85), similar distribution (p = 0.23), and little bias (y = 0.96x+28.14 mg/24 hr) existed between the predicted and measured PER for all patients with overt glucosuria (urine glucose ≥1000 mg/dL, n = 348). In summary, these data suggest that the established formula for predicted PER on RUS is equally valid for patients on or off SGLT2i, and that this result is a useful clinical estimating tool.
A-242 Validation of a Calculated Lipoprotein Insulin Resistance Score Using a Commercially Available NMR Spectrometer and Software
Hornseth, Jean M, Kurak, Julia, Vasile, Vlad C. , Jaffe, Allan S. , Meeusen, Jeff W., Miller, Joshua R. , Donato, Leslie J. , Jaffe, Allan S. , Meeusen, Jeffrey W.

Mayo Clinic

Clinical Chemistry | October 2, 2025 | Volume: 71 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvaf086.235 Get It

Abstract Background Insulin resistance leads to changes in lipid and lipoprotein metabolism prior to developing prediabetes, including an increase in the concentration of large very-low-density lipoprotein particles (LVLDL-p), the mean size of VLDL (VLDL-s), and the concentration of small low-density lipoprotein particles (sLDL-p). Conversely, there is a decrease in the concentration of large high-density lipoprotein particles (LHDL-p), mean size of HDL (HDL-s), and mean size of LDL (LDL-s). Clinically validated studies show that proton nuclear magnetic resonance (NMR) can measure these six parameters and derive a lipoprotein insulin resistance (LP-IR) score, ranging from 0 to 100, with higher scores indicating greater risk for insulin resistance. The reference method for calculating LP-IR relies on a proprietary NMR spectrometer, spectral deconvolution method, and algorithm. This study seeks to determine if lipoprotein subfraction parameters measured from a commercially available NMR system can produce LP-IR scores comparable to the reference method. Methods Serum lipoprotein NMR spectra were collected using a Bruker Ascend 600 MHz magnet, Bruker Avance NEO 500 spectrometer, and the Numares AXINON lipoFIT System to report the six LP-IR score parameters between January 2023 and January 2025 (Cohort A, n = 2,474). During the same period, LP-IR score and parameters were collected using the Vantera Clinical Analyzer (400 MHz) with the LipoProfile LP4 method (Cohort B, n = 2,959). Linear regression of decile-matched data for each parameter yielded adjustment equations to align lipoFIT values with the LipoProfile method. LP-IR scores were then calculated for both adjusted and unadjusted values using a previously published LP-IR scoring algorithm. Finally, LP-IR scores were compared for sera with measures from both instruments was (Cohort C, n = 108). Results The median concentrations of sLDL-p, LDL-s, VLDL-s, HDL-S matched between Cohort A and B (&lt;1% difference). Significant differences were noted for LVLDL-p and LHDL-p, with percent differences of 21.5% and 23.5%, respectively. Despite closely matching medians, the distributions varied greatly, with a mean interquartile range (IQR) percent difference across measures of 31.2% (Table 1). After distribution matching, all parameter median and mean IQR percent differences fell to &lt;5% and &lt;10%, respectively, between Cohort A and Cohort B. In Cohort C the LP-IR score matched well (y=1.1x-15, r=0.92; 95%CI 0.88, 0.94). Following distribution matching adjustment of lipoFIT values for Cohort C, new calculated LP-IR scores matched with reduced bias (y=0.94x-1.2) while correlation was slightly reduced (r=0.88 [0.83, 0.92]). By comparison, adjustments made via scaling lipoFIT values proportionally by the ratio of the medians between Cohort A and Cohort B yielded calculated LP-IR scores in Cohort C that maintained a similar bias prior to adjustments (y=1.2x-21), highlighting the ability of distribution matching to reduce bias. Conclusion Adjustments to measured lipoprotein parameters from a commercially available NMR spectrometer can be achieved via distribution matching. These adjustments greatly reduce the bias between a commercially available method and algorithm compared to the reference method, allowing for wider adoption of LP-IR score reporting.
Hemolysis or vitamin B12? Unveiling the impostor
Sullivan, Luz Y. , Miller, Joshua R. , Larson, Kenneth C., Gandhi, Manish J. , Gandhi, Manish , Miller, Joshua R , Larson, Kenneth C.

Mayo Clinic

Transfusion | March 19, 2025 | Volume: 65 | Issue: 5 | Pages: 797-798

10.1111/trf.18219 | PMID 40105875 Get It

Modulating limbic circuits in temporal lobe epilepsy: impacts on seizures, memory, mood and sleep
Křemen, Václav , Sladky, Vladimir , Mívalt, Filip , Gregg, Nicholas M. , Brinkmann, Benjamin H. , Balzekas, Irena , Marks, Victoria S. , Lundstrom, Brian N. , Cui, Jie, Alden, Eva , Fields, Julie A. , Crockett, Karla, Adolf, Jindřich , Bilderbeek, Jordan, Hermes, Dora, Miller, Kai J. , Bilderbeek, Jordan , Marks, Victoria S , Kucewicz, Michal, Lundstrom, Brian Nils , St Louis, E K , Croarkin, Paul E , Alden, Eva C, Messina, Steven, Miller, Kai Joshua, Van Gompel, Jamie, Brinkmann, Benjamin H , Kremen, Vaclav , Gregg, Nicholas M , Bilderbeek, Jordan A , Mivalt, Filip , Kucewicz, Michał T. , Cui, Jie , Louis, Erik K. St. , Croarkin, Paul E. , Joseph, Boney , Hermes, Dora , Messina, Steven A. , Gompel, Jamie J. Van , Denison, Timothy , Worrell, Gregory A.

Mayo Clinic

Brain Communications | March 7, 2025 | Volume: 7 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcaf106 | PMID 40196395 Get It

Abstract Temporal lobe epilepsy is a common neurological disease characterized by recurrent seizures that often originate within limbic networks involving amygdala and hippocampus. The limbic network is involved in crucial physiologic functions involving memory, emotion and sleep. Temporal lobe epilepsy is frequently drug-resistant, and people often experience comorbidities related to memory, mood and sleep. Deep brain stimulation targeting the anterior nucleus of the thalamus (ANT-DBS) is an established therapy for temporal lobe epilepsy. However, the optimal stimulation parameters and their impact on memory, mood and sleep comorbidities remain unclear. We used an investigational brain sensing-stimulation implanted device to accurately track seizures, interictal epileptiform spikes (IES), and memory, mood and sleep comorbidities in five ambulatory subjects. Wireless streaming of limbic network local field potentials (LFPs) and subject behaviour were captured on a mobile device integrated with a cloud environment. Automated algorithms applied to the continuous LFPs were used to accurately cataloged seizures, IES and sleep-wake brain state. Memory and mood assessments were remotely administered to densely sample cognitive and behavioural response during ANT-DBS in ambulatory subjects living in their natural home environment. We evaluated the effect of continuous low-frequency and duty cycle high-frequency ANT-DBS on epileptiform activity and memory, mood and sleep comorbidities. Both low-frequency and high-frequency ANT-DBS paradigms reduced seizures. However, continuous low-frequency ANT-DBS showed greater reductions in IES, electrographic seizures and better sleep and memory outcomes. These results highlight the potential of synchronized brain sensing and dense behavioural tracking during ANT-DBS for optimizing neuromodulation therapy. While studies with larger patient numbers are needed to validate the benefits of low-frequency ANT-DBS, these findings are potentially translatable to individuals currently implanted with ANT-DBS systems.
Pharmacogenetic Analysis of CYP2C19 for Clopidogrel: Ready for Prime Time
Miller, Joshua R. , Baudhuin, Linnea M. , Miller, Joshua R

Mayo Clinic

Clinical Chemistry | March 4, 2025 | Volume: 71 | Issue: 3 | Pages: 432-433

10.1093/clinchem/hvae203 | PMID 40037408 Get It

Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis
Qu, Wenchun , Engelberg-Cook, Erica , Yan, Dan , Siddik, Abu Bakar , Bu, Guojun , Allickson, Julie, Kubrova, Eva , Hare, Joshua M. , Pascual, Jorge M., Nayfeh, Tarek , Saadi, Samer , Durvasula, Ravindra, Richards, Elaine M. , Sanfilippo, Fred , Siddik, Abu Bakar , Allickson, Julie G, Hare, Joshua M , Kurtzberg, Joanne , Mallea, Jorge M. , Durvasula, Ravindra V, Bu, Guojun , Nayfeh, Tarek , Saadi, Samer , Wang, Zhen , Caplan, Arnold I. , Ricordi, Camillo , Pepine, Carl J. , Rodríguez, Ricardo López , March, Keith L.

Mayo Clinic

Stem Cells Translational Medicine | April 29, 2022 | Volume: 11 | Issue: 7 | Pages: 688-703

10.1093/stcltm/szac032 | PMID 35640138 Get It

Abstract MSC (a.k.a. mesenchymal stem cell or medicinal signaling cell) cell therapies show promise in decreasing mortality in acute respiratory distress syndrome (ARDS) and suggest benefits in treatment of COVID-19-related ARDS. We performed a meta-analysis of published trials assessing the efficacy and adverse events (AE) rates of MSC cell therapy in individuals hospitalized for COVID-19. Systematic searches were performed in multiple databases through November 3, 2021. Reports in all languages, including randomized clinical trials (RCTs), non-randomized interventional trials, and uncontrolled trials, were included. Random effects model was used to pool outcomes from RCTs and non-randomized interventional trials. Outcome measures included all-cause mortality, serious adverse events (SAEs), AEs, pulmonary function, laboratory, and imaging findings. A total of 736 patients were identified from 34 studies, which included 5 RCTs (n = 235), 7 non-randomized interventional trials (n = 370), and 22 uncontrolled comparative trials (n = 131). Patients aged on average 59.4 years and 32.2% were women. When compared with the control group, MSC cell therapy was associated with a reduction in all-cause mortality (RR = 0.54, 95% CI: 0.35-0.85, I 2 = 0.0%), reduction in SAEs (IRR = 0.36, 95% CI: 0.14-0.90, I 2 = 0.0%) and no significant difference in AE rate. A sub-group with pulmonary function studies suggested improvement in patients receiving MSC. These findings support the potential for MSC cell therapy to decrease all-cause mortality, reduce SAEs, and improve pulmonary function compared with conventional care. Large-scale double-blinded, well-powered RCTs should be conducted to further explore these results.
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings
Klonoff, David C. , Wang, Jing , Rodbard, David , Kohn, Michael A. , Li, Chengdong , Liepmann, Dorian , Kerr, David , Ahn, David , Peters, Anne L. , Umpierrez, Guillermo E. , Xu, Nicole Y. , Nguyen, Kevin T. , Simonson, Gregg D. , Agus, Michael S. D. , Armaiz-Peña, Gustavo , Basu, Ananda , Battelino, Tadej , Yeshiwas, Sewagegn , Bequette, B. Wayne , Blevins, Thomas , Breton, Marc D. , Castle, Jessica R. , Close, Kelly L. , Drincic, Angela, Dungan, Kathleen , Ejskjær, Niels , Espinoza, Juan , Fleming, G. Alexander , Forlenza, Gregory P. , Freckmann, Guido , Galindo, Rodolfo J. , Gómez, Ana María , Gutow, Hanna A. , Hovorka, Roman , Ji, Linong , Joubert, Michaël , Koliwad, Suneil K. , Lal, Rayhan , Lansang, M. Cecilia , Lee, Wei-An , Leelarathna, Lalantha , Lind, Marcus , Mahoney, Katherine , Mankovsky, Boris , Masharani, Umesh , Mathioudakis, Nestoras , Mayorov, Alexander Yur'evich , Messler, Jordan , Mohan, Viswanathan , Nichols, James H. , O’Neal, David N. , Pasquel, Francisco J. , Philis‐Tsimikas, Athena , Phillip, Moshe , Rayman, Gerry , Russell, Steven J. , Spanakis, Elias K. , Waki, Kayo , Wallia, Amisha , Weinberg, Melissa E. , Wolpert, Howard , Zilbermint, Mihail , Kovatchev, Boris , Seley, Jane Jeffrie , Xu, Nicole Y , Nguyen, Kevin T , Simonson, Gregg , Agus, Michael S D , Al-Sofiani, Mohammed E , Armaiz-Pena, Gustavo , Bailey, Timothy S , Basu, Ananda , Battelino, Tadej , Bekele, Sewagegn Yeshiwas , Benhamou, Pierre-Yves , Bequette, B Wayne , Blevins, Thomas , Breton, Marc D , Castle, Jessica R , Chase, James Geoffrey , Chen, Kong , Choudhary, Pratik , Clements, Mark A , Close, Kelly L , Cook, Curtiss B , Doyle, Francis J , Drincic, Angela , Dungan, Kathleen M , Edelman, Steven V , Ejskjaer, Niels , Espinoza, Juan , Fleming, G Alexander , Forlenza, Gregory P , Freckmann, Guido , Galindo, Rodolfo J , Gomez, Ana Maria , Gutow, Hanna A , Heinemann, Lutz , Hirsch, Irl B , Hoang, Thanh D , Hovorka, Roman , Jendle, Johan H , Ji, Linong , Joshi, Shashank R , Joubert, Michael , Koliwad, Suneil K , Lal, Rayhan A , Lansang, M Cecilia , Lee, Wei-An Andy , Leelarathna, Lalantha , Leiter, Lawrence A , Lind, Marcus , Litchman, Michelle L , Mader, Julia K , Mahoney, Katherine M , Mankovsky, Boris , Masharani, Umesh , Mathioudakis, Nestoras N , Mayorov, Alexander , Messler, Jordan , Miller, Joshua D , Mohan, Viswanathan , Nichols, James H , Nørgaard, Kirsten , O'Neal, David N , Pasquel, Francisco J , Philis-Tsimikas, Athena , Pieber, Thomas , Phillip, Moshe , Polonsky, William H , Pop-Busui, Rodica , Rayman, Gerry , Rhee, Eun-Jung , Russell, Steven J , Shah, Viral N , Sherr, Jennifer L , Sode, Koji , Spanakis, Elias K , Wake, Deborah J , Waki, Kayo , Wallia, Amisha , Weinberg, Melissa E , Wolpert, Howard , Wright, Eugene E , Zilbermint, Mihail , Kovatchev, Boris , Kohn, Michael , Umpierrez, Guillermo E. , Peters, Anne L , Ahn, David T , Liepmann, Dorian , Bailey, Timothy S. , Chen, Kong Y. , Choudhary, Pratik , Cook, Curtiss B. , Danne, Thomas , Doyle, Francis J. , Heinemann, Lutz , Hirsch, Irl B. , Leiter, Lawrence A. , Mader, Julia K. , Pop‐Busui, Rodica , Shah, Viral N. , Sode, Koji , Wright, Eugene E.

Mayo Clinic

Journal of Diabetes Science and Technology | March 29, 2022 | Volume: 17 | Issue: 5 | Pages: 1226-1242

10.1177/19322968221085273 | PMID 35348391 Get It

Background: A composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful for assisting with basic clinical interpretation of CGM data. Methods: We assembled a data set of 14-day CGM tracings from 225 insulin-treated adults with diabetes. Using a balanced incomplete block design, 330 clinicians who were highly experienced with CGM analysis and interpretation ranked the CGM tracings from best to worst quality of glycemia. We used principal component analysis and multiple regressions to develop a model to predict the clinician ranking based on seven standard metrics in an Ambulatory Glucose Profile: very low–glucose and low-glucose hypoglycemia; very high–glucose and high-glucose hyperglycemia; time in range; mean glucose; and coefficient of variation. Results: The analysis showed that clinician rankings depend on two components, one related to hypoglycemia that gives more weight to very low-glucose than to low-glucose and the other related to hyperglycemia that likewise gives greater weight to very high-glucose than to high-glucose. These two components should be calculated and displayed separately, but they can also be combined into a single Glycemia Risk Index (GRI) that corresponds closely to the clinician rankings of the overall quality of glycemia (r = 0.95). The GRI can be displayed graphically on a GRI Grid with the hypoglycemia component on the horizontal axis and the hyperglycemia component on the vertical axis. Diagonal lines divide the graph into five zones (quintiles) corresponding to the best (0th to 20th percentile) to worst (81st to 100th percentile) overall quality of glycemia. The GRI Grid enables users to track sequential changes within an individual over time and compare groups of individuals. Conclusion: The GRI is a single-number summary of the quality of glycemia. Its hypoglycemia and hyperglycemia components provide actionable scores and a graphical display (the GRI Grid) that can be used by clinicians and researchers to determine the glycemic effects of prescribed and investigational treatments.
Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome
Qu, Wenchun , Hare, Joshua M. , Bu, Guojun , Pascual, Jorge M., Caplan, Arnold I. , Zubair, Abba C. , Kubrova, Eva , Engelberg-Cook, Erica , Nayfeh, Tarek , Shah, Vishal P. , Hill, James C. , Wolf, Michael E. , Murad, M. Hassan , Sanfilippo, Fred , Hare, Joshua M , Mallea, Jorge M. , Caplan, Arnold I , Zubair, Abba C , Wolf, Michael E , Murad, M Hassan , Bu, Guojun , Nayfeh, Tarek , Wang, Zhen , Kurtzberg, Joanne , Prokop, Larry J.

Mayo Clinic

Stem Cells Translational Medicine | May 30, 2020 | Volume: 9 | Issue: 9 | Pages: 1007-1022

10.1002/sctm.20-0146 | PMID 32472653 Get It

AbstractSevere cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 117 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO2/FiO2 ratio, alveolo-capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.Significance statement The potential benefits of mesenchymal stromal cell (MSC) therapy for patients with COVID-19 acute respiratory distress syndrome support the rapid commencement of clinical trials, as well as the compassionate use of MSCs that already have documented safety profiles from FDA-approved studies.